A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies for obstructive sleep apnea and other sleep disorders
For media enquiries relating to this topic, please contact:
Headlines in this article
Related news and insights
News: 26 January 2024
News: 18 January 2024
News: 05 January 2024
A&O advises Shionogi & Co., Ltd. (Shionogi), on its strategic collaboration and joint venture with Apnimed, Inc. (Apnimed) to develop therapies for obstructive sleep apnea (OSA) and other sleep disorders.
The transaction is structured as a 50:50 joint venture through a limited liability company incorporated in Delaware, United States, Shionogi-Apnimed Sleep Science, LLC.
The joint venture will leverage the Shionogi's innovation skills and small molecule drug discovery capabilities, and Apnimed's knowledge and R&D capabilities in the OSA field and approach to new combination treatments for OSA; with a view to realising promising solutions for OSA and other sleep disorders at a speed that cannot be achieved alone.
The A&O team was led by Matthew Appleton (Partner and Global Head of Healthcare Transactions, London), David Ingles (Partner, New York), Tokutaka Ito (Partner, Tokyo) and Jim Ford (Partner, and Global Head of Life Sciences, London), supported by Soumya Sharma (Senior Counsel, New York), Zara Sproul (Senior Associate, London), Megan McMellon (Associate, London) and Lucy Chen (Associate, New York).
For further information, please contact Clemency Wells on email@example.com.